GSK Stock Recent News

British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage trial.

GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).

British pharmaceuticals giant GSK PLC (LSE:GSK, NYSE:GSK) has presented late-breaking data at the European Respiratory Society (ERS) International Congress, highlighting a 54% reduction in severe asthma exacerbations in patients treated with depemokimab. The findings are based on the Phase III AReS study, which focused on patients with eosinophilic asthma.

British drugmaker GSK on Friday announced positive results from its late-stage trial of asthma drug Nucala in treating chronic obstructive pulmonary disease (COPD), also known as smoker's lungs.

The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive.

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?

The European Commission approves GSK's RSV vaccine, Arexvy, for use in adults aged 50-59 years with increased risk of the disease.

GSK's cheap valuation, reasonable stock price appreciation and bright growth potential indicate that investors should stay invested.

The European Commission has approved the expanded use of GSK PLC (LSE:GSK, NYSE:GSK)'s Arexvy, its respiratory syncytial virus (RSV) vaccine, to include adults aged 50 to 59 at increased risk due to underlying medical conditions. It allows for the jab's use ahead of the upcoming RSV season across Europe.

GSK shares jumped Wednesday on news Delaware's top court ruled in the pharmaceutical company's favor, by agreeing to review the admissibility of expert evidence that could play a part in the British firm's legal fight against claims its Zantac heartburn drug causes cancer.